Archive | Innovation Challenge RSS feed for this section

The Innovation Challenge for Digital RESI September is Accepting Applications!

30 Jul

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN


One of the biggest challenges facing fundraising CEOs working to bridge the gap between potential and partnership is the ability to stand out among a sea of promising tech and connect with the right investors for their work. Life Science Nation (LSN) wants to make the choices clearer for investors, which is why we’ve developed the Innovation Challenge for early-stage companies.  The Innovation Challenge is designed to highlight the best of the best so deserving companies can showcase their work to strategic partners.

The Innovation Challenge for the 3-Day Digital Redefining Early Stage Investments (RESI) Conference in September is now accepting applications for two weeks only, due August 12!

For fundraising life science companies, participating in the Innovation Challenge is a great way to increase visibility. All participating companies will have a dedicated landing page featuring materials (example screenshot below) that the companies can use to promote and direct traffic, just like they would do at an in-person RESI.

In addition, they will be featured on the Next Phase blog and newsletter, as well as LSN’s social networking platforms. Finalists also are indicated with a special badge within our partnering system indicating their Innovation Challenge Finalist status.

Attendees are also encouraged to vote for their favorite, most innovative companies and the Top 3 Winners who receive the most votes can receive free tickets for up to 3 future RESI Conferences of their choice.

The Innovation Challenge review team has compiled a list of guidelines to help companies with their application process:

What makes a high-score company?

The evaluation process is based not only on scientific merit, but also on how ready the company is to present to an investor (“investor-readiness”). A perfectly scored company would have a transformational technology that can achievably address a high unmet need using a differentiable novel approach or target. Alongside high innovation, differentiation, unmet need, and market fit, a high-scoring company would have a broad IP position, an experienced management team and CEO with top-tier advisors, and strategic alliances with manufacturing and clinical partners. The company will also receive high marks for having what we call “investor-ready” marketing material (executive summary, pitch deck, website).

Clearly describe your technology.

Like any marketing material, you need to be clear. Be sure you understand and answer the questions fully. The team has seen unclear responses as to what a company’s technology is and its significance in improvement.

Be honest with your answers.

The team frequently reviews applications that state they have no competitors in the space, when most likely, they do. Novel products do have competitors before them, for established technology does exist in the indication your product targets. Be honest with whom your competitors are, and then address what the key differentiators are to your product. Even if your product is an incremental improvement, be honest and highlight this and it can still be attractive!

For example, competitors for your disease-modifying therapeutic may be symptom-treating therapeutics in the same indication that are either commercialized or being developed. You should identify these symptom-treating therapeutics and highlight your novel target approach that makes your product disease-modifying.

Explain your current standings in detail.

Outline everything you have in terms of your current standing, while also providing your outlook of where you hope to go. Avoid ambiguous statements such as, “CEO is an experienced entrepreneur”. Instead, provide details that highlight the CEO’s experience – years as an entrepreneur, number and names of companies exited, background expertise, etc.

Provide short-range and long-term horizons.

If you do not have certain criteria, such as a strategic alliance or IP, that’s perfectly fine. State your current standing and provide what steps you are currently taking to reach that milestone. For Alliances and Collaborations, state your verbal relationships; for IP status, state how many you have filed or are planning to file. Providing your strategy is better than a simple yes or no.

Put in a balanced effort.

You should not spend 5 minutes on this application, and neither should you spend 5 hours. Your answers should be brief, as well as detailed – the team has received hasty, effortless applications that are quickly discarded with a low score. On the other hand, you also shouldn’t spend an excessive amount of time on the application, as these are all straight-forward questions that you should be comfortable answering. Remember, as your executive summary should answer all these questions alone, this application is the backbone of the evaluation process and essentially your executive summary.

Send us your marketing material.

If you have marketing material, send it. This includes your slide deck, executive summary, website, videos – any supplemental material that can boost understanding of your technology and whether your company is investor-ready. The application provides limited space – while this forces you to get straight to the point, supplemental material explains what an application cannot (i.e. figures, graphs, pipeline, non-confidential data, etc.)

Companies can submit their applications for the Digital RESI September Innovation Challenge by August 12 at here. Learn more about Digital RESI September at

Increase Your Exposure at Digital RESI September

2 Jul

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN


We are excited to announce the launch of two opportunities to increase your company’s exposure at the Digital Redefining Early Stage Investments (RESI) Conference in September – The Innovation Challenge and Featured Company Pitch Sessions.

Showcase Your Technology at the Innovation Challenge

This marks our third time organizing the Innovation Challenge in a digital format. The Innovation Challenge is always a great opportunity to increase your exposure and showcase your technology. 30 finalists will be selected from a pool of over 100 applicants, and all companies will have their own dedicated page to upload their virtual poster, video, and other supplementary materials. RESI attendees will be able to vote for up to 5 companies that they find the most innovative.

If you are interested in increasing your visibility to 400+ investors, please apply! The deadline is Wednesday, August 12th.

Pitch Your Company to a Panel of Investors

The Featured Company Pitch Session is a great opportunity to gain exposure for your company and get valuable feedback from a panel of investors. For an added fee, companies get a dedicated page featuring their pitch, followed by a virtual Q&A session with a panel of investors and a live audience. Applications are accepted on a rolling basis, so make sure to submit your application as soon as possible!

Congratulations to Our Digital RESI June Innovation Challenge Winners!

11 Jun

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN


Our 3-day Digital RESI June conference came to an end yesterday, and we are very excited to announce the Top 3 Winners of the Innovation Challenge. Each participating finalist company had a dedicated page where you could view their virtual poster, short pitch, and other supplementary materials that the companies made available for viewing.

We will keep our Digital RESI June “live agenda” page open to the public for another month, so if you have not had the chance already, please visit Digital RESI June Live Agenda to see our virtual exhibit of some amazing technologies across therapeutics, medical devices, diagnostics, and digital health!

We would like to thank every Innovation Challenge company for their virtual presentations, and the hard work they put in to promote their technologies to RESI attendees. In all, we hope that all companies were able to make the most out of the digitally presented Innovation Challenge.

The Top 3 winners will be awarded with free tickets to future RESI conferences. Congratulations to the Top 3 winners, and thank you all for casting your votes!

First Place: Sen-Jam Pharmaceutical

Click Here to Check Out Sen-Jam Pharmaceutical’s Digital Poster

Sen-Jam Pharmaceutical is a therapeutics company focused on rapidly developing drugs to reduce pain and inflammation. We do this by combining approved FDA drugs that have never been combined before to create new formulations. Our 3 lead drugs are at varying stages of development for treatments including Viral Respiratory Infections (e.g. COVID-19), Opioid Withdrawal, and Alcohol Hangover prevention. We have 24+ Patents awarded and pending.

Jacqueline Iversen, RPh, MS, Head of Clinical Development, Sen-Jam Pharmaceutical | Jim Iversen, CEO/COO, Sen-Jam Pharmaceutical

Second Place: AyuVis Research

Click Here to Check Out AyuVis Research’s Digital Poster

AyuVis Research, Inc. is a late preclinical stage pharmaceutical company with novel small molecule compounds for treating complicated respiratory diseases like bronchopulmonary dysplasia (BPD), bacterial pneumonia, acute respiratory distress syndrome (ARDS) and systemic inflammatory syndrome (sepsis). A pre-IND meeting with the FDA is completed. The compounds modulate the innate immune system to control hyperinflammation and eliminate microbial pathogens. AyuVis’ new class of drug can also prevent and treat conditions like severe COVID-19 infection related lung injuries, ARDS, multiple organ failure and death, where traditional protocols have had limited results. Preclinical testing in animal models have demonstrated effective results for intravenous (IV), intranasal (IN), and intraperitoneal (IP) administration of the drug depending on the target disease and tissue being treated.

Suchismita Acharya, PhD, President and CEO & Management Team

Third Place: Oxidien Pharmaceuticals

Click Here to Check Out Oxidien Pharmaceuticals’ Digital Poster

Oxidien Pharmaceuticals is a clinical stage drug development company developing a treatment for enteric hyperoxaluria, a large unmet need in kidney disease. We have excellent safety and efficacy data using our proprietary, oral biologic with significant advantages over products in development. Enteric hyperoxaluria is a condition that affects 250,000 patients in the US alone. The company spun out from Captozyme, Inc., in 2019, before Captozyme was acquired by Arranta Bio in November of 2019. Oxidien is now presenting a de-risked opportunity for an investment partner to come in early as we get ready for a dose-finding Phase 2 study.

Helena Cowley, CEO, Oxidien Pharmaceuticals

Digital RESI June 2020: Innovation Challenge Finalists Announced!

21 May

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claireOur 3-day Digital RESI June Conference is coming up in less than 3 weeks, and we are very excited to announce our Innovation Challenge finalists. With a diverse representation across therapeutics, medical devices, diagnostics, and digital health, these companies were selected on the basis of innovative technology, strong management team, clear pathway to commercialization, and other positive factors that demonstrated high growth potential.

This will be our second time organizing a “digital” Innovation Challenge, and each company will have a dedicated webpage as part of our virtual conference agenda. These pages will feature a virtual poster and any non-confidential materials they would like to share with the conference attendees. Attendees will be able to vote for their favorite technologies during the 3-day span, and the Top 3 winners will be announced at the end of the conference and featured on our weekly LSN newsletter of 36,000 subscribers on Thursday.

We would like to thank all applicants for their interest in the upcoming RESI and our Innovation Challenge. Congratulations to the selected finalists – please see their clickable logos below!


Medical Devices


Digital Health

Apply for the Digital RESI Innovation Challenge

16 Apr

By Karen Deyo, Senior Investor Research Analyst, LSN

Our Digital RESI taking place on June 8-10th is just around the corner, and companies will once again be able to showcase their technologies through the RESI Innovation Challenge. Companies can apply to participate, and the review team will use the LSN Expert System to select the 30 most ‘investable’ companies to be featured. Each company will have their own dedicated site to present their poster digitally, as well as any other non-confidential material they wish to share. These companies will compete for votes among RESI attendees, with the top three companies winning prizes. Click here to complete the application. Don’t wait too long, as the application deadline is May 6th!





RESI Europe 2020 Innovation Challenge – Check Out the Finalists!

5 Mar

By Claire Jeong, Director of Research, Asia BD, LSN


With less than 3 weeks left until our second RESI Europe conference, we are very excited to announce the RESI Europe Innovation Challenge finalists. The RESI team received applications from all across the globe, boasting an even stronger diversity than our inaugural RESI Europe in Vienna last year.

All registered RESI attendees will receive 5 “RESI Cash”, which they can use to “invest” in the most promising Innovation Challenge companies. As always, we highly encourage all attendees to reserve some time during the conference to browse around the exhibit hall and engage with the finalists who will be eager to pitch their company and the innovative work they are doing to address unmet medical needs.

Thank you for everyone who applied for the Innovation Challenge. For those of you who were not selected, please look out for future opportunities including RESI San Diego (June) and RESI Boston (September).

Congratulations again to the selected RESI Europe Innovation Challenge companies – please see them below!



Medical Device

Digital Health



RESI’s Innovation Challenge Drove A Seed Round for This Medtech Startup – Interview with Yuan-Ren Cheng, COO of Heroic-Faith Medical Science

20 Feb

Yuan-Ren Cheng

An interview with Yuan-Ren Cheng, COO of Heroic-Faith Medical Science

– By Jessica Yang, Investor Research Analyst, LSN

Jessica Yang

International early-stage companies often seek cross-border investment opportunities and strategic partnerships. How do these companies start at the beginning? What can they do to meet global investors and expand beyond regionally available resources? LSN invites 10 different types of investors from across the globe to meet with early stage companies at the RESI conferences, allowing companies to take advantage of the chance to meet many investors who are a fit for them in one day. I recently spoke to Yuan-Ren Cheng, COO of Heroic-Faith Medical Science, who won second place in the RESI San Francisco 2019 Innovation Challenge and successfully raised their seed round. Heroic-Faith Medical Science is a Taiwan-based medical device company developing AI-powered respiratory monitor for the critical care medicine.

Jessica Yang (JY): Congratulations on raising your seed round! What is the recent progress of your company?

Yuan-Ren Cheng (YRC): Thank you! We raised our seed financing round of $2.96 million, and we are looking to raise our Series A round for $7 million this year. Our exciting story was that, before we attended RESI SF last year, we had secured only $900K for our seed round, and after RESI SF, we raised an extra of $2.06 M to make it $2.96 M in capital. We grew from 7-8 team members to 21 employees now. We also received our key patent in the US recently, and we expect our device to receive US FDA clearance this year.

JY: That’s amazing! How do you think RESI helped you?

YRC: I think applying for Innovation Challenge was an important decision for us. We got selected as a finalist at our first RESI and won second place. This helped us gain a lot of exposure via RESI’s newsletter announcement and promotion for the top 3 Innovation Challenge winners, and RESI’s media partners also promoted our company and technology. I think this make our respiratory monitor became more famous.

Besides some investors from Taiwan that we’d seen before, most investors are new to us. We got 11 confirmed meetings at our first RESI, including big firms like Siemens. Interestingly, though the VP of Business Development from Siemens told us we weren’t a fit for their investment focus, she still sees our product promising and further introduced her connections in the patient monitor area. This is the power of RESI! You get to meet right people in similar industries at RESI, and if you are well-prepared, you could get even more opportunities from these people. That’s why we always recommend other startups that we know to apply for Innovation Challenge and proactively attend RESI.

JY: What was your strategy of sending out meeting requests in the RESI partnering platform?

YRC: We sent 100+ meeting requests through the partnering platform. We especially increased our efforts in the week before RESI. We noticed that many investors start to lock down their schedules in the week prior to the conference, and that’s why we sent follow-up messages in the partnering system to grab their attention. Also, we regularly researched the partnering system for newly added investors. We searched and sorted hundreds of investors in the partnering system, then we prepared three kinds of executive summaries targeting different categories of investors that fit us. For example, we had executive summaries specifically for Medtech investors, Healthcare IT investors, and investors who are interested in pulmonary and cardiovascular sectors.

JY: How do you think Innovation Challenge is different from other startup competitions? What is the key advantage of Innovation Challenge?

YRC: Overall, I think RESI really organizes the Innovation Challenge very well! The RESI team provided instructive information to let everyone know the purpose of this competition is for startups to network with investors at their poster. It’s very straightforward and condensed, and the Innovation Challenge allows us to have interactions with many RESI attendees. We got tons of business cards and recognized new business opportunities because of the Innovation Challenge. This is crucial to us because we know whom to contact and with whom to follow up after the conference. After all, you need a list to send your emails with company updates.

Speaking of this, I will also recommend that two people from the same company attend RESI together, to allow one to focus on partnering meetings and the other to stay at the Innovation Challenge poster. I think this is the most productive way to attend RESI.

JY: In your seed round you also raised money from non-Taiwan investors, what is your suggestions to international companies who are currently fundraising?

YRC: I think one point is that international startups have to step out and attend global conferences like RESI. Looking for cross-border partnership isn’t an easy task. We know that some investors with geographical restrictions of their investments could be the barrier. But if you have strong arguments to convince other global investors with your actual execution and performance, I think there are always chances to get funding. For example, you really need to understand the unmet medical needs, digitize your company’s progress, and even find out the advantages from where you’re based. This is also why RESI is such a great platform that you can keep attending the conferences and following up with potential opportunities. Otherwise, you won’t know where to start and find targets that aren’t based in your region. You can also learn what other early-stage companies are developing in RESI and analyze your competitiveness.

JY: Thank you so much for sharing your story!

Established in June 2018, Heroic-Faith Medical Science Corp., LTD. is focused on the development of medical devices for the critical care medicine. The total annual spending on ICU care in North America in 2018 reaches $108 billion USD, being second only to cancer care which totals $158 billion USD, making it a key market that is marked by costly spending, as well as one that is open to new ideas. We hope to combine Taiwan’s advanced medical expertise with its cutting-edge electronics capabilities to develop break-through products, so that we can realize the ideal of our CEO, “Saving lives through innovation”, in the global market.


%d bloggers like this: